safety

October 31, 2018

New Compound Safely Halts Advanced Myeloma Progression in Small Pilot Study

News

A new investigational compound targeting a central pathway in cancer development showed promising results in patients with relapsed or refractory multiple myeloma in a small Phase 1/2a pilot trial. ... Read more

September 12, 2018

Poseida’s Potential CAR T-cell Therapy Shows Positive Early Results in Phase 1 Multiple Myeloma Trial

News

Poseida Therapeutics’ CAR T-cell therapy candidate P-BCMA-101 is showing superior safety over alternatives and significant effectiveness in patients with relapsed or refractory multiple myeloma, according to early results of ... Read more

July 9, 2018July 9, 2018

Twice‐weekly Ninlaro Combo Improves Outcomes in Newly Diagnosed Myeloma Patients, Trial Shows

News

Twice‐weekly Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone can improve long-term outcomes in patients with newly diagnosed multiple myeloma, although it’s likely more toxic than once-weekly Ninlaro, according to ... Read more

March 19, 2018March 19, 2018

Myeloma Patients Refractory to Revlimid May Benefit from Ninlaro, Pomalyst, Dexamethasone Combo

News

Multiple myeloma patients who failed prior Revlimid (lenalidomide) treatment may benefit from a triple oral combo treatment with Ninlaro (ixazomib), Pomalyst (pomalidomide) and dexamethasone, the results of a Phase 1/2 clinical study ... Read more

February 28, 2018February 28, 2018

Xgeva Use in Myeloma May Be Expanded to Europe Following Positive CHMP Opinion

News

Treatment of bone lesions in multiple myeloma patients with Amgen’s Xgeva (denosumab) may be expanded to European patients following a positive opinion from the E.U. regulatory entity Committee for Medicinal ... Read more

January 15, 2018

Potential Myeloma Therapy Shows Positive Interim Phase 2 Trial Results, According to Report

News

Molecular Partners‘ multiple myeloma treatment candidate MP0250 showed positive preliminary safety and effectiveness results in an ongoing Phase 2 clinical study, according to the biopharmaceutical company. The first dose (8 mg ... Read more

December 8, 2017December 8, 2017

FDA Allows Trials of Opdivo Combo Therapy to Resume, Signaling No New Safety Concerns

News

The U.S. Food and Drug Administration (FDA) agreed to allow two clinical trials of Opdivo (nivolumab)-based combinations for myeloma to resume, after being put on partial hold in September 2017, ... Read more

October 27, 2017October 27, 2017

Cellectar Expands Phase 1 Trial to Evaluate Multiple Dosing of CLR 131 in Myeloma Patients

News

Cellectar Biosciences is expanding its Phase 1 dose-escalating trial to evaluate the effectiveness and safety of multiple administrations of CLR 131 for the treatment of relapsed or refractory multiple myeloma. The trial’s ... Read more

October 6, 2017October 6, 2017

Cellectar’s CLR 131 Shows Positive Phase 1 Trial Results for Heavily Treated Myeloma Patients

News

All three relapsed or refractory multiple myeloma patients in the final group of Cellectar Biosciences‘ Phase 1 trial of CLR 131 benefited from treatment, researchers said. Participants had received more than five ... Read more

September 8, 2017December 8, 2017

Safety Concerns About Other Therapies Prompt FDA to Put a Hold on Three Opdivo Combo Trials

News

The U.S. Food and Drug Administration has ordered Bristol-Myers Squibb to put a hold on three clinical trials evaluating Opdivo (nivolumab) in combination with immunomodulatory drugs as a treatment ... Read more